★ Five-year follow-up data for lorlatinib show prolonged progression-free survival in ALK-positive advanced lung cancer
Pfizer today announced long-term follow-up results from the CROWN study7.8Phase III trial evaluating lorlatinib (▼Lorviqua®),…
0 Comments